Clinical trial NCT02962947 - References

Melanoma — MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients

Citation(s)

•   Aronow WS
  Current role of beta-blockers in the treatment of hypertension. Expert Opin Pharmacother. 2010 Nov;11(16):2599-607. doi: 10.1517/14656566.2010.482561. Review.
•   Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K
  Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol. 2011 Jul 1;29(19):2635-44. doi: 10.1200/JCO.2010.33.5422.
•   Bielecka-Dabrowa A, Aronow WS, Rysz J, Banach M
  Current place of beta-blockers in the treatment of hypertension. Curr Vasc Pharmacol. 2010 Nov;8(6):733-41. Review.
•   Chen JM, Heran BS, Perez MI, Wright JM
  Blood pressure lowering efficacy of beta-blockers as second-line therapy for primary hypertension. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD007185. doi: 10.1002/14651858.CD007185.pub2. Review.
•   Cruickshank JM
  Are we misunderstanding beta-blockers. Int J Cardiol. 2007 Aug 9;120(1):10-27. Review.
•   De Giorgi V, Gandini S, Grazzini M, Benemei S, Marchionni N, Geppetti P
  Effect of ß-blockers and other antihypertensive drugs on the risk of melanoma recurrence and death. Mayo Clin Proc. 2013 Nov;88(11):1196-203. doi: 10.1016/j.mayocp.2013.09.001.
•   De Giorgi V, Grazzini M, Gandini S, Benemei S, Lotti T, Marchionni N, Geppetti P
  Treatment with ß-blockers and reduced disease progression in patients with thick melanoma. Arch Intern Med. 2011 Apr 25;171(8):779-81. doi: 10.1001/archinternmed.2011.131.
•   Lamy S, Lachambre MP, Lord-Dufour S, Béliveau R
  Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. Vascul Pharmacol. 2010 Nov-Dec;53(5-6):200-8. doi: 10.1016/j.vph.2010.08.002.
•   Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A
  Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008 Jun 12;358(24):2649-51. doi: 10.1056/NEJMc0708819.
•   Lemeshow S, Sørensen HT, Phillips G, Yang EV, Antonsen S, Riis AH, Lesinski GB, Jackson R, Glaser R
  ß-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2273-9. doi: 10.1158/1055-9965.EPI-11-0249.
•   Lyons KE, Pahwa R
  Pharmacotherapy of essential tremor : an overview of existing and upcoming agents. CNS Drugs. 2008;22(12):1037-45. doi: 10.2165/0023210-200822120-00006. Review.
•   Miller AJ, Mihm MC Jr
  Melanoma. N Engl J Med. 2006 Jul 6;355(1):51-65. Review.
•   Ozeki M, Fukao T, Kondo N
  Propranolol for intractable diffuse lymphangiomatosis. N Engl J Med. 2011 Apr 7;364(14):1380-2. doi: 10.1056/NEJMc1013217.
•   Perron L, Bairati I, Harel F, Meyer F
  Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control. 2004 Aug;15(6):535-41.
•   Tsao H, Atkins MB, Sober AJ
  Management of cutaneous melanoma. N Engl J Med. 2004 Sep 2;351(10):998-1012. Review. Erratum in: N Engl J Med. 2004 Dec 2;351(23):2461.
•   Williams B
  Beta-blockers and the treatment of hypertension. J Hypertens. 2007 Jul;25(7):1351-3.
•   Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, Volmink J
  Beta-blockers for hypertension. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002003. Review. Update in: Cochrane Database Syst Rev. 2012;8:CD002003.

Melablock: A Multicentre Randomized, Double---blinded and Placebo---controlled Clinical Trial on the Efficacy and Safety of Once Daily Propranolol 80 mg Retard for the Prevention of Cutaneous Malignant Melanoma Recurrence

Details for clinical trial NCT02962947